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Summary
Relaxin family peptide receptor 1 (RXFP1), the cognate receptor for relaxin, is a G-protein cou-
pled receptor (GPCR) possessing a unique extracellular region consisting of a domain of 10 leu-
cine rich repeats (LRRs) linked to an N-terminal low density lipoprotein Class A module. Relax-
in binds to its receptor primarily by a high affinity interaction with the LRRs. An additional 
low-affinity interaction has been proposed to occur between relaxin and the the exoloops (ELs) 
of the transmembrane domain, however the molecular detail of this interaction remains unde-
fined.
While site directed mutagenesis and subsequent functional characterisation of these mutants 
traditionally allows identification of residues contributing to receptor function, in this case 
results are complicated by the presence of the high affinity binding site in the LRRs. To create a 
tool to investigate the low-affinity interaction, a protein scaffold system displaying exoloops 1 
and 2 from RXFP1 was designed. This was achieved by inserting RXFP1 exoloops 1 and 2 into 
the native loops of a thermostabilised 6 kDa GB1 protein creating EL1/EL2-GB1. This protein 
has been expressed and purified in milligram quantities and used in conjunction with biophysi-
cal techniques such as NMR to explore relaxin binding to the exoloops of RXFP1.
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RXFP1 is a unique class-A G protein-coupled receptor (GPCR) belonging to the 
leucine rich repeat (LRR) family defined by an extracellular domain containing 10 
LRRs linked to an N-terminal low-density lipoprotein class-A module. The LRRs 
form the primary high-affinity binding site for relaxin (Bathgate, 2006., Bullesbach, 
2005). Furthermore a low-affinity binding site involving EL2 within the transmem-
brane domain has been suggested (Halls, 2005., Sudo, 2003). Molecular characterisa-
tion of relaxin binding to the low-affinity site in the full length receptor is complicat-
ed and masked by the presence of the high-affinity site within the LRRs, requiring an 
alternate approach for investigation (Kong, 2010).
Consequently, a soluble protein scaffold containing EL1 and EL2 from RXFP1 was 
designed to probe relaxin binding to the exoloops in isolation from the high-affinity 
binding site. The design, expression and purification of this engineered protein are 
described below.
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Design of a scaffold containing exoloops of RXFP1 (EL1/EL2-GB1)
A thermostabilised variant of streptococcal protein G (GB1) was chosen to use as 
the scaffold to display EL1 and EL2 from RXFP1, based on previous success (Datta, 
2003). The scaffold has two sites introduced into juxtaposed loops for sequence inser-
tion in a GPCR like orientation (Figure 1). 
RXFP1 loop sequences were determined using transmembrane prediction software 
(http://www.cbs.dtu.dk/services/TMHMM) and incorporated into tGB1 flanked by Gly 
linkers to generate EL1/EL2-GB1. The linkers add flexibility within the loops to enable 
formation of native conformations. One key structural feature of these loops is a disul-
phide bond connecting the C-terminal of EL1 with the middle of EL2 which mimics the 
native disulphide linkage between the ELs in the native RXFP1 (Hsu, 2002).
Expression and Purification of EL1/EL2-GB1
EL1/EL2-GB1 was expressed as an N-terminal His6-tag fusion in BL21 (DE3) 
Escherichia coli after induction with 0.5 mM IPTG, 16°C for 24 hours. Protein was 
extracted from inclusion bodies after cell lysis and repeat washes (50 mM Tris, 100 
mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 1 mM DTT pH 8) in addition to a deter-
gent-free wash before solubilisation in 8 M urea at 4°C. Protein was then purified 
on Ni-Sepharose Fast Flow resin (GE Healthcare) under denaturing conditions (8 M 
urea, 1 M NaH2PO4, 10 mM Tris) and eluted at pH 4. The protein was refolded in 3 
Figure 1. Schematic of the design of EL1/EL2-GB1. Exoloops predicted to form a low-affinity binding site for 
relaxin to its receptor (RXFP1) were inserted into juxtaposed loops of GB1 generating a soluble protein scaf-
fold displaying the loops of interest. This scaffold can be used to probe for an interaction between these 
loops and the ligand relaxin.
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M urea (500 mM NaCl, 50 mM Tris, 50 mM glycine, 100 mM glucose, 4 mM reduced 
glutathione, 0.4 mM oxidised glutathione) then 1 M urea (500 mM NaCl, 50 mM Tris, 
50 mM glycine, 100 mM glucose, 4 mM reduced glutathione, 0.4 mM oxidised glu-
tathione) at room temperature prior to overnight dialysis in 20 mM Tris pH 8. Pro-
tein was further purified on DEAE beads (GE Healthcare) using a NaCl gradient with 
EL1/EL2-GB1 elution at 100-200 mM NaCl prior to final purification on a Hiload 
16/60 Superdex 75 gel filtration column (GE Healthcare). Yields of 5 mg/L culture 
are routinely obtained and protein identity and disulphide bond formation was con-
firmed by ESI-TOFF mass spectrometry.
Results/Discussion:
The scaffold was engineered to display defined RXFP1 EL sequences accounting 
for the flexibility required within the loops and the disulphide bond between EL1 
and EL2 conserved in most GPCRs. A method for the adequate expression and purifi-
cation of EL1/EL2-GB1 has been established and the identity of the purified protein, 
including confirmation of the formation of the critical disulphide bond, was deter-
mined by mass spectrometry. 
A new tool has been produced for investigating the secondary ligand binding site 
within RXFP1. Being a small soluble protein, ligand interactions with the loops on 
this scaffold can be assessed by a number of biophysical techniques such as Nuclear 
Magnetic Resonance spectroscopy to allow identification of interacting residues. Ulti-
mately, this will enhance our understanding of RXFP1 activation which is important 
for drug design at this receptor.
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